Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | April 25, 2014 | April 29, 2014 |
| Amesite Inc.NONE · Entity 149985 | Director | March 31, 2020 | April 06, 2020 |
| Amesite Inc.AMST · Entity 8151 | Director | September 30, 2026 | October 03, 2026 |
| Elicio Therapeutics, Inc.ANGN · Entity 299 | Director | June 09, 2022 | June 13, 2022 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Director | April 17, 2017 | April 19, 2017 |
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 25, 2014 · Filed April 29, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,547 |
Reported balance
After 2014-04-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2014-04-25 · Grant · Acquired 1,795 · Balance 180,547 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.
F2: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
Amesite Inc.
Report date March 31, 2020 · Filed April 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-03-31 | Direct | 50,000 |
Reported balance
After 2020-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-31 · Grant · Acquired 50,000 · Balance 50,000 F1: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-03-31 | Direct | 10,000 |
Reported balance
After 2020-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-31 · Grant · Acquired 10,000 · Balance 10,000 F2: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter.
F2: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter.
Amesite Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Gilbert S. Omenn Revocable Trust | 95,927 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 12,121 · Balance 95,927 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AMST common stock and/or the cash equivalent of such share. F2: The reported securities were issued as "deferred stock units" in lieu of cash compensation earned for services as a director, and the number of deferred stock units received was calculated based on the closing share price on the last day of the quarter. The deferred stock units or cash equivalent will be issued to the reporting person upon completion of service as a member of the board of directors or, if earlier, a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AMST common stock and/or the cash equivalent of such share.
F2: The reported securities were issued as "deferred stock units" in lieu of cash compensation earned for services as a director, and the number of deferred stock units received was calculated based on the closing share price on the last day of the quarter. The deferred stock units or cash equivalent will be issued to the reporting person upon completion of service as a member of the board of directors or, if earlier, a change in control.
Elicio Therapeutics, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2032-06-09 | Direct | 15,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 15,000 · Balance 15,000 F1: 1.To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1.To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Esperion Therapeutics, Inc.
Report date April 17, 2017 · Filed April 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2027-04-17 | Direct | 14,000 |
Reported balance
After 2017-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-17 · Grant · Acquired 14,000 · Balance 14,000 F1: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017.
GALECTIN THERAPEUTICS INC
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-01-16 | Direct | 60,000 |
Reported balance
After 2026-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2: The options vest 100% on December 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest 100% on December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2005 Filed Mar 8, 2005 18:17 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $62.50 | $62,500.00 |
DisclosureSEC source: 0001181431-05-015245 · rrd71678.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| February 11, 2005 Filed Feb 14, 2005 21:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $63.27 | $63,270.00 |
DisclosureSEC source: 0001181431-05-009551 · rrd68512.xml · nonDerivative · entry 6 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| February 11, 2005 Filed Feb 14, 2005 21:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $63.31 | $63,310.00 |
DisclosureSEC source: 0001181431-05-009551 · rrd68512.xml · nonDerivative · entry 5 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| February 11, 2005 Filed Feb 14, 2005 21:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $63.41 | $63,410.00 |
DisclosureSEC source: 0001181431-05-009551 · rrd68512.xml · nonDerivative · entry 4 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| February 11, 2005 Filed Feb 14, 2005 21:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $63.57 | $63,570.00 |
DisclosureSEC source: 0001181431-05-009551 · rrd68512.xml · nonDerivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| February 11, 2005 Filed Feb 14, 2005 21:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $63.90 | $63,900.00 |
DisclosureSEC source: 0001181431-05-009551 · rrd68512.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| February 11, 2005 Filed Feb 14, 2005 21:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,000 | $63.15 | $126,300.00 |
DisclosureSEC source: 0001181431-05-009551 · rrd68512.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,011 F1 · balance_after: (GSO 2.05) Does not include (i) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P., and (ii) 5,590 shares held indirectly by the reporting person's son. Read SEC document |
| January 19, 2005 Filed Jan 19, 2005 21:21 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 18,400 | $0.00 Strike: $7.67 | $0.00 |
DisclosureSEC source: 0001181431-05-003557 · rrd65219.xml · derivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,400 shares Expires 2005-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2005 Filed Jan 19, 2005 21:21 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,200 | $64.16 | $141,152.00 |
DisclosureSEC source: 0001181431-05-003557 · rrd65219.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,011 F1 · balance_after: (GSO-12.09.04) Does not include .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| January 19, 2005 Filed Jan 19, 2005 21:21 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 18,400 | $7.67 | $141,162.96 |
DisclosureSEC source: 0001181431-05-003557 · rrd65219.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: (GSO-12.09.04) Does not include .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| December 09, 2004 Filed Dec 9, 2004 21:12 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 340 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-04-057726 · rrd60790.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 5,590 Read SEC document |
| December 09, 2004 Filed Dec 9, 2004 21:12 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 1,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-04-057726 · rrd60790.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,811 F1 · balance_after: (GSO-12.09.04) Does not include .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| March 15, 2004 Filed Mar 16, 2004 21:10 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $59.48 | $0.00 |
DisclosureSEC source: 0001181431-04-015903 · rrd36769.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2011-03-15 Read SEC document |
| March 15, 2004 Filed Mar 16, 2004 21:10 UTC | AMGEN INC AMGN · Entity 2832 | GrantRestricted Stock Units | 1,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-04-015903 · rrd36769.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,643 F1 · security: (DIR 03.15.04) The Restricted Stock Units ("RSUs") were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. F2 · balance_after: (GSO-03.15.04) Does not include: (i) 159,188 shares of common stock directly owned by reporting person, (ii) 5,250 shares of common stock held by the son of reporting person, and (iii) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A intrests of Amgen Clinical Partners, L.P. Read SEC document |
| January 21, 2004 Filed Jan 21, 2004 21:48 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 22,400 | $6.19 Strike: $6.19 | $138,600.00 |
DisclosureSEC source: 0001181431-04-003630 · rrd29679.xml · derivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,400 shares Expires 2004-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2004 Filed Jan 21, 2004 21:48 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,201 | $62.95 | $138,552.95 |
DisclosureSEC source: 0001181431-04-003630 · rrd29679.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,188 F1 · balance_after: (GSO-12/9/03) Does not included: (i) 5,250 shares held by the son of reporting person, and (ii) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| January 21, 2004 Filed Jan 21, 2004 21:48 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 22,400 | $6.19 | $138,600.00 |
DisclosureSEC source: 0001181431-04-003630 · rrd29679.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: (GSO-12/9/03) Does not included: (i) 5,250 shares held by the son of reporting person, and (ii) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| December 09, 2003 Filed Dec 10, 2003 19:12 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-03-034913 · rrd25242.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,989 F1 · balance_after: (GSO-12/9/03) Does not include: (i) 5,250 shares held by the son of the reporting person, and (ii) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
| December 08, 2003 Filed Dec 9, 2003 21:23 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-03-034777 · rrd25016.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,714 F1 · balance_after: (1) (GSO-12/8/03) Does not include: (i) 5,250 shares held by the son of reporting person, and (ii) .5 unit of contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinical Partners, L.P. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.